Commentary: Fundamental limitations of meta-analysis of cohort studies, epidemiological challenges and the stage of obesity epidemic by Xu, L & Lam, TH
Title
Commentary: Fundamental limitations of meta-analysis of
cohort studies, epidemiological challenges and the stage of
obesity epidemic
Author(s) Lam, TH; Xu, L
Citation International Journal of Epidemiology, 2017, v. 46 n. 2, p. 547-548
Issued Date 2017
URL http://hdl.handle.net/10722/242094
Rights
This is a pre-copy-editing, author-produced PDF of an article
accepted for publication in International Journal of
Epidemiology following peer review. The definitive publisher-
authenticated version International Journal of Epidemiology,
2017, v. 46 n. 2, p. 547-548 is available online at:
https://academic.oup.com/ije/article-
abstract/46/2/547/2739040?redirectedFrom=fulltext; This work is
licensed under a Creative Commons Attribution-
NonCommercial-NoDerivatives 4.0 International License.
Fundamental limitations of meta-analysis of cohort studies, epidemiological challenges and 
the stage of obesity epidemic. 
Tai Hing Lam, MD1, Lin Xu, PhD1 
 
1 School of Public Health, the University of Hong Kong, Hong Kong  
 
 
Corresponding author: Professor Tai Hing Lam 
School of Public Health, The University of Hong Kong 
Hong Kong, China 
Tel: (852) 3917 9287; Fax: (852) 2855 9528 
Email: hrmrlth@hku.hk 
 
Conflict-of-interest: The authors have no competing interests. 
  
Meta-analysis can generate useful results but can be controversial or confusing. Flegal’s meta-
analysis showed over-weight did not increase mortality risk1 but a much larger meta-analysis 
found over-weight did increase risk when the analysis was restricted to nonsmokers at baseline.2 
Both were based on baseline BMI and did not account for health and obesity status before and 
after baseline. But both showed clearly that obesity kills. World Health Organization advocates 
for healthy diet and physical activity to halt the rise of global obesity, but weight reduction is not 
highlighted.3 
 
Karahalios and colleagues’meta-analysisis the first to show that weight loss and weight gain in 
midlife are associated with increased risk of all-cause and cardiovascular disease mortality, and 
weakly associated with cancer mortality.4 They discussed weight loss intention, effect 
modification, reverse causation, bias and confounding, and stated that “this is the highest level of 
evidence possible” and “these observational data suggest weight stability from middle age, 
however, further research investigating effect modification by obesity status is warranted.”4 
 
Although the authors did not recommend weight stability regardless of health and weight status, 
the results based on observational data could be easily misinterpreted with adverse public health 
implications. Our interpretation is that their result that weight gain showed higher risk than 
weight stability is plausible and can confirm that increased adiposity is harmful. Such increased 
risk can be more easily observed when obesity has been rapidly increasing globally during the 
follow up period of the cohorts, and we would expect more unhealthy weight gain and related 
harms than healthy weight reduction and related benefits in many cohort studies.  However, the 
result that higher risk for weight reduction is unexpected and more problematic, which is most 
likely due to reverse causation, as the adverse effects of unintentional weight loss due to ill health 
and aging in many subjects would overwhelm the benefits of intentional weight loss in the few.  
 
The fundamental limitation of meta-analysis of observational studies is the lack of data on 
lifestyle, health, adiposity, intervention and weight loss intention in the life-course before 
baseline and during follow-up. These factors may add to, counteract, or overwhelm the effects of 
weight changes. 
 
For cohort studies, the first challenge is to assess weight fluctuation (i.e., weight loss after weight 
gain, or weight gain after weight loss) at multiple time points. Reliable and affordable methods 
for long-term monitoring of weight trajectory are needed. The second challenge is to determine 
the reasons and methods by which weight change is achieved in people with different weight 
trajectory, health and disease status, and lifestyle changes (such as stopping smoking) and effects 
of treatment. The third challenge is to go beyond BMI and collect data for other indicators of 
adiposity, and biomarkers using new technologies. The fourth is aging, which typically leads to 
loss of lean body mass and muscle strength, and increase in fat mass. Statistical adjustment for 
age will mask effect modification. The assessment of effect modification needs to consider the 
age range of the subjects included, insufficient statistical power, and length of follow up (a long 
follow up is needed for younger subjects for mortality).  The results from a failure to observe 
significant effect modification by age does not mean that the results can be generalised to all 
people at middle age or other ages. The same applies to no significant interaction by baseline 
weight status or weight reduction intention, and the results cannot be generalised to all people 
regardless of the above variations.   
 
Given the many difficulties in observation studies, Mendelian randomization (MR) using genetic 
variants that predict individuals who are more prone to weight gain or weight loss as instrumental 
variables can provide analogous evidence to randomised controlled trials (RCTs). MR has been 
increasingly used to clarify causal relationships from observational studies and to prioritise 
potential targets for intervention.5 But evidence on the effects of weight changes from 
intervention studies, especially from RCTs, is still urgently needed. RCTs on weight reduction in 
people with under- or normal weight, and on weight increase in people with normal or overweight 
are unethical. RCTs on weight reduction interventions on those who are overweight or obese can 
evaluate the cost effectiveness of different interventions on different target groups. The effects of 
weight stability can be assessed within RCTs by comparing those with weight changes (increase 
or decrease) with those with no change. 
 
More importantly, meta-analyses on the effects of a risk (or protective) factor at baseline or the 
change of a risk factor from baseline to follow up, need to be interpreted in relation to evidence 
from intervention studies to reduce (or increase) exposure to the risk factor. A 2015 meta-analysis 
of RCTs showed a 15% lower all-causal mortality risk with an average weight loss of 5.5 kg in 
those with mean BMI of 30-46 kg/m2.6 As meta-analyses on RCTs can provide much stronger 
evidence than meta-analyses on observational studies, we recommend that the RCT evidence, and 
weight reduction interventions, should be highlighted in future WHO fact sheets.  
The most important and never ending challenge is that the obesity epidemic is still at the early 
stage as obesity prevalence is increasing. The ‘stage of epidemic’ model was first used for 
tobacco, which shows a gap of a few decades between the peak of smoking prevalence and the 
peak of percentage of death attributable to tobacco.7 Cohort studies on smoking set up more 
recently or with subjects born more recently showed higher risks than cohorts set up or subjects 
born earlier (in the US and UK: relative risk for all-cause mortality has increased from 2 to 3).8 
The benefits of mortality risk reduction from quitting, based on follow up data of stopping 
smoking in smokers at baseline, can only become clear after a few decades of follow up. As 
obesity prevalence started to rise several decades later than smoking prevalence, more adverse 
effects of obesity will emerge from more recent research. Because of the long latent period and 
the cumulative effects of obesity over time (obesity starting at infancy and childhood, rate of 
increase, and severity and duration of obesity), past cohort studies on overweight and obesity 
would yield under-estimated risks. 
 
While ill health will always be a major cause of weight loss, with increasing obesity control 
measures, healthy weight loss would increase, and has been observed, such as in Hong Kong9 and 
Guangzhou10 China. Such changes, reasons for the changes and subsequent health benefits should 
be monitored and analysed. Moreover, the benefits may vary by the magnitude of change, the 
lifetime trajectory of weight status, the age at which weight loss started and duration of persistent 
weight loss. Hence, large biobank cohort studies (0.5 to 1 million subjects, including younger 
subjects) need to be set up periodically (every 10 years) in countries at different stages of the 
obesity epidemic, with data and biomaterial collection at baseline (including past health related 
data) and follow up (including reasons/methods of weight change) using more standardized 
methods, to allow for individual participant data meta-analyses. A large international 
collaboration is urgently needed. Otherwise, epidemiology in general, or cohort studies in 
particular, will always lag behind the evolution of the obesity epidemic. 
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